Gilead, JAKed About Cancer Research, Buys YM BioScienses
This article was originally published in The Pink Sheet Daily
Executive Summary
Gilead will buy the Canadian cancer specialist for $510 million, gaining the lead drug CYT387, a JAK1/JAK2 inhibitor that has demonstrated positive results in myelofibrosis patients.